Damaged lysosomes are repaired by a lipid-based signaling pathway dubbed PITT that could be targeted to treat neurodegenerative disease, its discoverers say.
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.